LYSSA
MCID: RBS001
MIFTS: 63

Rabies (LYSSA)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 77 54 60 56 44 45 15 74 3
Lyssa 12 54

Characteristics:

Orphanet epidemiological data:

60
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Rabies

MedlinePlus : 44 Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals Don't let pets roam Don't approach stray animals. Animals with rabies might be aggressive and vicious, or tired and weak Centers for Disease Control and Prevention

MalaCards based summary : Rabies, also known as lyssa, is related to encephalitis and viral encephalitis, and has symptoms including fever and pruritus. An important gene associated with Rabies is PML (Promyelocytic Leukemia), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Neomycin and Vancomycin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are depressivity and nausea and vomiting

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

CDC : 3 Rabies is a preventable viral disease of mammals most often transmitted through the bite of a rabid animal. The vast majority of rabies cases reported to the Centers for Disease Control and Prevention (CDC) each year occur in wild animals like raccoons, skunks, bats, and foxes.

Wikipedia : 77 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 encephalitis 29.8 CCL5 CXCL10 DDX58 IRF3 TLR3
2 viral encephalitis 29.8 CCL5 CXCL10 MX1
3 mouth disease 29.7 IRF3 MX1 STAT1 TLR3
4 herpes simplex 29.6 DDX58 IRF3 PML TLR3
5 tick-borne encephalitis 29.6 ALB CXCL10 TLR3
6 measles 29.4 DDX58 STAT1 STAT2 TLR3
7 japanese encephalitis 29.2 CCL5 CXCL10 DDX58 STAT1 TLR3
8 avian influenza 29.1 CXCL10 DDX58 STAT2
9 influenza 28.9 CCL5 DDX58 IRF3 MX1 PML TLR3
10 human immunodeficiency virus type 1 28.7 CCL5 CXCL10 IRF3 NFKB1 STAT1 TLR3
11 acute hemorrhagic leukoencephalitis 11.1
12 vaccinia 10.4
13 neuroblastoma 10.3
14 intestinal perforation 10.2 NCAM1 NFKB1
15 stomatitis 10.2
16 purpura 10.2
17 aleutian mink disease 10.2 ALB NGFR
18 lymphocytic choriomeningitis 10.1
19 myelitis 10.1
20 microphthalmia with limb anomalies 10.1 MX1 STAT1 STAT2
21 human t-cell leukemia virus type 2 10.1 NFKB1 STAT1
22 noonan syndrome 5 10.1 STAT1 STAT2
23 ocular motor apraxia 10.1
24 neuritis 10.1
25 tetanus 10.1
26 anthrax disease 10.1
27 acrodermatitis 10.1 ALB CXCL10
28 chronic nk-cell lymphocytosis 10.1 CCL5 NCAM1
29 dengue hemorrhagic fever 10.0 ALB STAT1 STAT2 TLR3
30 brucellosis 10.0
31 guillain-barre syndrome 10.0
32 encephalopathy 10.0
33 acute cervicitis 10.0 CCL5 CXCL10
34 malaria 10.0
35 status epilepticus 10.0
36 lichen planus 10.0
37 priapism 10.0
38 yellow fever 10.0
39 herpes simplex encephalitis 10.0
40 new-onset refractory status epilepticus 10.0
41 transverse myelitis 10.0
42 polyarteritis nodosa, childhood-onset 9.9
43 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
44 leukemia 9.9
45 erythema multiforme 9.9
46 mumps 9.9
47 common cold 9.9
48 meningoencephalitis 9.9
49 eastern equine encephalitis 9.9
50 st. louis encephalitis 9.9

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Human phenotypes related to Rabies:

60 33 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 depressivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0000716
2 nausea and vomiting 60 33 hallmark (90%) Very frequent (99-80%) HP:0002017
3 hallucinations 60 33 hallmark (90%) Very frequent (99-80%) HP:0000738
4 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
5 attention deficit hyperactivity disorder 60 33 hallmark (90%) Very frequent (99-80%) HP:0007018
6 anxiety 60 33 hallmark (90%) Very frequent (99-80%) HP:0000739
7 anorexia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002039
8 migraine 60 33 hallmark (90%) Very frequent (99-80%) HP:0002076
9 paresthesia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003401
10 diarrhea 60 33 hallmark (90%) Very frequent (99-80%) HP:0002014
11 recurrent pharyngitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100776
12 insomnia 60 33 hallmark (90%) Very frequent (99-80%) HP:0100785
13 vocal cord paresis 60 33 hallmark (90%) Very frequent (99-80%) HP:0001604
14 excessive salivation 60 33 hallmark (90%) Very frequent (99-80%) HP:0003781
15 cerebral palsy 60 33 frequent (33%) Frequent (79-30%) HP:0100021
16 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
17 sudden cardiac death 60 33 occasional (7.5%) Occasional (29-5%) HP:0001645
18 reduced consciousness/confusion 60 33 occasional (7.5%) Occasional (29-5%) HP:0004372
19 behavioral abnormality 60 Very frequent (99-80%)

UMLS symptoms related to Rabies:


fever, pruritus

MGI Mouse Phenotypes related to Rabies:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.96 ALB CXCL10 DDX58 IKBKE IRF3 NCAM1
2 hematopoietic system MP:0005397 9.81 CCL5 CXCL10 DDX58 NFKB1 NGFR PML
3 homeostasis/metabolism MP:0005376 9.65 ALB CXCL10 DDX58 IKBKE IRF3 NFKB1
4 immune system MP:0005387 9.36 CCL5 CXCL10 DDX58 IKBKE IRF3 NFKB1

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neomycin Approved, Vet_approved Phase 4,Phase 1 1404-04-2 8378
2
Vancomycin Approved Phase 4 1404-90-6 441141 14969
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Atovaquone Approved Phase 4 95233-18-4 74989
5
Proguanil Approved Phase 4 500-92-5 4923
6
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
7
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
8
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
9 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Antibodies, Blocking Phase 4,Phase 2,Not Applicable
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Bacterial Agents Phase 4,Phase 1
16 Antibiotics, Antitubercular Phase 4,Phase 1
17 Antirheumatic Agents Phase 4,Phase 2
18 Antimetabolites Phase 4,Phase 2,Not Applicable
19 Antiparasitic Agents Phase 4,Phase 3
20 Antitubercular Agents Phase 4
21 Antiprotozoal Agents Phase 4,Phase 3
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Chloroquine diphosphate Phase 4 50-63-5
26 Peripheral Nervous System Agents Phase 4
27 Atovaquone, proguanil drug combination Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29 Antimalarials Phase 4,Phase 3
30 Anthelmintics Phase 4
31
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
32
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
33
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
34
Lactitol Investigational Phase 3 585-86-4, 585-88-6 493591
35 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 1,Not Applicable
36 gamma-Globulins Phase 2, Phase 3,Phase 1,Not Applicable
37 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 1,Not Applicable
38 Laxatives Phase 3
39 Cathartics Phase 3
40 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
41 Complement C3 Phase 3
42 Pharmaceutical Solutions Phase 3
43 Anti-Infective Agents, Urinary Phase 3
44 Renal Agents Phase 3
45
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
46
Abacavir Approved, Investigational Phase 2 136470-78-5 441300 65140
47
Zidovudine Approved Phase 2 30516-87-1 35370
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Lamivudine Approved, Investigational Phase 2,Not Applicable 134678-17-4 60825
50
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Diagnostic Immunization With Rabies Vaccine in Patients With PID Unknown status NCT02490956 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules Completed NCT01365494 Phase 4
5 Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG Completed NCT01137045 Phase 4
6 Immunogenicity of Rabies Vaccine for Pre Exposure Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
7 A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children Completed NCT02991872 Phase 4
8 Immunogenicity and Safety of Verorab™ in Indian Population Completed NCT00260351 Phase 4
9 The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
10 Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics Recruiting NCT03557008 Phase 4 Metronidazole;Vancomycin;Neomycin Sulfate
11 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
12 Non-specific Effects of Rabies Vaccine Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
13 Safety of Rabivax-S for Pre-exposure Prophylaxis Enrolling by invitation NCT03741270 Phase 4
14 A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children Withdrawn NCT03192371 Phase 4
15 Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
16 Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age Completed NCT02177032 Phase 3
17 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
18 Early Rabies Vaccine Immunization in Primary School Children Completed NCT01107275 Phase 3
19 Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine Completed NCT01339312 Phase 3
20 A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Completed NCT02491541 Phase 3
21 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed NCT01662440 Phase 3
22 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Completed NCT01680016 Phase 3
23 Purified Rabies Vaccine for Human Use (Chick-embryo Cell) Completed NCT00345319 Phase 3
24 Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Completed NCT00825305 Phase 3
25 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans Completed NCT02288286 Phase 3
26 Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen Completed NCT01622062 Phase 3
27 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
28 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
29 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Completed NCT00866619 Phase 3
30 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Recruiting NCT02912845 Phase 3 KamRAB - HRIG
31 Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year Recruiting NCT03700242 Phase 3
32 A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. Active, not recruiting NCT02545517 Phase 3
33 Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects Active, not recruiting NCT03264157 Phase 2, Phase 3 HRIG
34 Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Active, not recruiting NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
35 One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding Unknown status NCT02276625 Phase 2
36 Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine Unknown status NCT00652275 Phase 2
37 Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
38 Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Completed NCT01930357 Phase 2
39 Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen Completed NCT01877395 Phase 2
40 Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use Completed NCT01784874 Phase 2
41 A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines Completed NCT02956746 Phase 1, Phase 2
42 Immunogenicity and Safety of a Purified Vero Rabies Vaccine Completed NCT03145766 Phase 2
43 Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults Completed NCT00948272 Phase 2
44 Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults Completed NCT01228383 Phase 2
45 Rabies Immunization Concomitant With JEV in Children Completed NCT00703521 Phase 2
46 Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents Completed NCT00708084 Phase 2
47 A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
48 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
49 Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Completed NCT00694460 Phase 2
50 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali Completed NCT00460525 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

MalaCards organs/tissues related to Rabies:

42
Brain, Testes, Spinal Cord, B Cells, Skin, T Cells, Cortex

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 3135)
# Title Authors Year
1
Multinational survey shows low awareness of tick-borne encephalitis and rabies among travellers to endemic regions. ( 30561667 )
2019
2
Paralytic rabies: A Guillain-Barre Syndrome mimic. ( 30830154 )
2019
3
Commentary: Cerebrospinal fluid changes in cattle with rabies or with BoHV-5 meningoencephalitis and its correlation with the severity of CNS inflammatory process. ( 30704752 )
2019
4
Genetic and spatial characterization of the red fox (Vulpes vulpes) population in the area stretching between the Eastern and Dinaric Alps and its relationship with rabies and canine distemper dynamics. ( 30861028 )
2019
5
Spatiotemporal distribution of a non-haematophagous bat community and rabies virus circulation: a proposal for urban rabies surveillance in Brazil. ( 30868985 )
2019
6
Molecular detection of rabies virus strain with N-gene that clustered with China lineage 2 co-circulating with Africa lineages in Monrovia, Liberia: first reported case in Africa. ( 30868993 )
2019
7
Using roaming behaviours of dogs to estimate contact rates: the predicted effect on rabies spread. ( 30869048 )
2019
8
Comparative study of rabies antibody titers of dogs vaccinated in Finland and imported street dogs vaccinated abroad. ( 30871641 )
2019
9
Canine Rabies in the Brazil-Bolivia Border Region from 2006 to 2014. ( 30873769 )
2019
10
Feline herpesvirus vectored-rabies vaccine in cats: A dual protection. ( 30878247 )
2019
11
Frugivorous bats in the Colombian Caribbean region are reservoirs of the rabies virus. ( 30890183 )
2019
12
Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines. ( 30890382 )
2019
13
Analysis on the risks of severe adverse events in rabies post-exposure prophylaxis and appropriate decision-making procedure. ( 30892986 )
2019
14
A new recombinant rabies virus expressing a green fluorescent protein: A novel and fast approach to quantify virus neutralizing antibodies. ( 30898479 )
2019
15
Purification of IgG against ribonucleoprotein by a homemade immunoaffinity chromatography column for rabies diagnosis. ( 30904384 )
2019
16
Toll-Like Receptor 7 Enhances Rabies Virus-Induced Humoral Immunity by Facilitating the Formation of Germinal Centers. ( 30906301 )
2019
17
Cost Savings of Using Updated Thai Red Cross Intradermal Regimen in a High-Throughput Anti-Rabies Clinic in New Delhi, India. ( 30909481 )
2019
18
A cross-sectional study of knowledge regarding rabies among attendees of anti-rabies clinic of a teaching hospital, Jaipur. ( 30911505 )
2019
19
Statistical analysis of the usefulness of follicle-sinus complexes as a novel diagnostic material for canine rabies. ( 30531131 )
2019
20
A reply to "A comment on "Factors influencing the outcome of primary immunization against rabies in young dogs"". ( 30567631 )
2019
21
Human Rabies Postexposure Prophylaxis Knowledge and Retention Among Health Professionals by Using an Online Continuing Education Module: Arizona, 2012 to 2015. ( 30581988 )
2019
22
Of bats and livestock: The epidemiology of rabies in Trinidad, West Indies. ( 30593386 )
2019
23
Human Rabies - Virginia, 2017. ( 30605446 )
2019
24
Canine rabies control and human exposure 1951-2015, Guangzhou, China. ( 30618465 )
2019
25
RACCOON ( PROCYON LOTOR) RESPONSE TO ONTARIO RABIES VACCINE BAITS (ONRAB) IN ST. LAWRENCE COUNTY, NEW YORK, USA. ( 30620627 )
2019
26
Epidemiological aspects of the persistent transmission of rabies during an outbreak (2010 - 2017) in Harare, Zimbabwe. ( 30629634 )
2019
27
The reemergence of human rabies and emergence of an Indian subcontinent lineage in Tibet, China. ( 30640911 )
2019
28
Knowledge, attitudes and practices (KAP) towards rabies and free-roaming dogs (FRD) in Shirsuphal village in western India: A community based cross-sectional study. ( 30682015 )
2019
29
Priorities in applied research to ensure programmatic success in the global elimination of canine rabies. ( 30685249 )
2019
30
Assessment of naturally acquired neutralizing antibodies against rabies Lyssavirus in a subset of Nunavik's Inuit population considered most at risk of being exposed to rabid animals. ( 30688040 )
2019
31
Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen. ( 30691982 )
2019
32
Knowledge, attitudes, and practices regarding rabies in Grenada. ( 30695024 )
2019
33
Utility of rabies neutralizing antibody detection in cerebrospinal fluid and serum for ante-mortem diagnosis of human rabies. ( 30695032 )
2019
34
Human rabies post-exposure prophylaxis relative to the disease epidemiological status. ( 30698264 )
2019
35
Rabies post-exposure prophylaxis initiation and adherence among patients in Vietnam, 2014-2016. ( 30723063 )
2019
36
Exosomes Released from Rabies Virus-Infected Cells May be Involved in the Infection Process. ( 30725320 )
2019
37
Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course. ( 30737043 )
2019
38
Taking the bait: species taking oral rabies vaccine baits intended for raccoons. ( 30737717 )
2019
39
Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. ( 30753961 )
2019
40
Early Events in Rabies Virus Infection-Attachment, Entry, and Intracellular Trafficking. ( 30772332 )
2019
41
Rabies Prophylaxis Strategy in Iran, a Need for an Alternative Strategy: Would the Essen Regimen be Replaced by Zagreb Protocol? ( 30775880 )
2019
42
Challenges to human rabies elimination highlighted following a rabies outbreak in bovines and a human in Punjab, India. ( 30779303 )
2019
43
Rabies postexposure prophylaxis in international travellers: Results from a Spanish travellers referral unit. ( 30795908 )
2019
44
RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. ( 30797640 )
2019
45
Evaluating the contact rate between companion dogs during dog walking and the practices towards potential cases of rabies among dog owners in Japan. ( 30810290 )
2019
46
Determinants of health seeking behavior of animal bite victims in rabies endemic South Bhutan: a community-based contact-tracing survey. ( 30813935 )
2019
47
Sociodemographic factors which predict low private rabies vaccination coverage in dogs in Blantyre, Malawi. ( 30819860 )
2019
48
Deficient Incorporation of Rabies Virus Glycoprotein into Virions Enhances Virus-Induced Immune Evasion and Viral Pathogenicity. ( 30836694 )
2019
49
Natural Infection with Rabies Virus: A Histopathological and Immunohistochemical Study of Human Brains. ( 30847265 )
2019
50
Immunogenicity of Potomac Horse Fever vaccine when simultaneously co-administered with rabies vaccine in a multivalent vaccine or as two monovalent vaccines at separate sites. ( 30859618 )
2019

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCL5 CXCL10 DDX58 IFNA4 IKBKE IRF3
2
Show member pathways
13.43 CCL5 IFNA4 IKBKE NFKB1 NGFR STAT1
3
Show member pathways
13.27 CCL5 CXCL10 IKBKE NFKB1 NGFR STAT1
4
Show member pathways
13.17 CCL5 CXCL10 DDX58 IFNA4 IRF3 MX1
5
Show member pathways
13.08 CCL5 CXCL10 IFNA4 IKBKE IRF3 NFKB1
6
Show member pathways
12.9 CCL5 DDX58 IFNA4 IKBKE IRF3 NFKB1
7
Show member pathways
12.86 IFNA4 IKBKE IRF3 MX1 NFKB1 NGFR
8
Show member pathways
12.78 CCL5 CXCL10 NFKB1 STAT1 STAT2
9 12.73 IFNA4 NFKB1 PML STAT1 STAT2
10
Show member pathways
12.7 CCL5 CXCL10 DDX58 IFNA4 IKBKE IRF3
11
Show member pathways
12.59 IKBKE NFKB1 NGFR TLR3
12
Show member pathways
12.58 IKBKE NFKB1 PML STAT1
13
Show member pathways
12.52 IKBKE IRF3 NFKB1 NGFR TLR3
14
Show member pathways
12.35 DDX58 IFNA4 IRF3 MX1 NCAM1 PML
15
Show member pathways
12.33 DDX58 IRF3 NFKB1 TLR3
16
Show member pathways
12.31 IKBKE IRF3 NFKB1 TLR3
17
Show member pathways
12.3 IFNA4 IKBKE STAT1 STAT2
18
Show member pathways
12.24 IKBKE NFKB1 STAT1 STAT2
19
Show member pathways
12.23 IFNA4 IRF3 MX1 NGFR PML STAT1
20
Show member pathways
12.21 IFNA4 NFKB1 STAT1 STAT2
21
Show member pathways
12.2 IKBKE IRF3 NFKB1 STAT1 TLR3
22 12.17 CCL5 CXCL10 DDX58 IKBKE IRF3 NCAM1
23
Show member pathways
12.16 IKBKE IRF3 NFKB1 TLR3
24
Show member pathways
12.12 CCL5 CXCL10 IKBKE NFKB1 TLR3
25
Show member pathways
12.11 IKBKE NFKB1 STAT1 STAT2
26
Show member pathways
12.11 IFNA4 STAT1 STAT2 TLR3
27 12.04 NFKB1 PML STAT1
28
Show member pathways
12.03 IKBKE NFKB1 NGFR
29 12.02 NCAM1 NFKB1 NGFR STAT1
30 11.97 ALB NCAM1 NGFR
31
Show member pathways
11.97 CCL5 NGFR STAT1 STAT2
32
Show member pathways
11.95 STAT1 STAT2 TLR3
33 11.94 NFKB1 STAT1 STAT2
34
Show member pathways
11.92 NFKB1 STAT1 TLR3
35
Show member pathways
11.88 CCL5 CXCL10 DDX58 IFNA4 IKBKE IRF3
36 11.86 CCL5 CXCL10 NFKB1
37 11.78 IFNA4 IKBKE STAT1 STAT2
38 11.29 CXCL10 STAT1 STAT2
39 11.05 CCL5 NFKB1
40
Show member pathways
10.92 DDX58 IRF3 MX1 STAT1 STAT2

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 ALB CCL5 CXCL10 IFNA4 IGHM NCAM1

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.96 CCL5 CXCL10 NFKB1 TLR3
2 innate immune response GO:0045087 9.95 DDX58 IGHM IRF3 MX1 PML TLR3
3 cytokine-mediated signaling pathway GO:0019221 9.91 CCL5 CXCL10 IFNA4 STAT1 STAT2
4 defense response GO:0006952 9.86 CXCL10 IFNA4 MX1 TLR3
5 negative regulation of angiogenesis GO:0016525 9.82 CXCL10 PML STAT1
6 viral process GO:0016032 9.8 DDX58 IKBKE IRF3 NCAM1 PML STAT1
7 cellular response to interferon-gamma GO:0071346 9.79 CCL5 STAT1 TLR3
8 interferon-gamma-mediated signaling pathway GO:0060333 9.73 IRF3 NCAM1 PML STAT1
9 positive regulation of type I interferon production GO:0032481 9.72 IRF3 NFKB1 TLR3
10 negative regulation of type I interferon production GO:0032480 9.71 DDX58 IKBKE IRF3
11 positive regulation of interferon-beta production GO:0032728 9.67 DDX58 IRF3 TLR3
12 positive regulation of defense response to virus by host GO:0002230 9.66 DDX58 STAT1
13 cellular response to interferon-beta GO:0035458 9.65 STAT1 TLR3
14 positive regulation of monocyte chemotaxis GO:0090026 9.65 CCL5 CXCL10
15 cellular response to exogenous dsRNA GO:0071360 9.63 DDX58 TLR3
16 positive regulation of T cell migration GO:2000406 9.63 CCL5 CXCL10
17 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.63 IKBKE IRF3 TLR3
18 membrane protein intracellular domain proteolysis GO:0031293 9.62 NFKB1 NGFR
19 response to exogenous dsRNA GO:0043330 9.62 DDX58 IFNA4 IRF3 TLR3
20 I-kappaB phosphorylation GO:0007252 9.61 IKBKE TLR3
21 positive regulation of lipid storage GO:0010884 9.6 IKBKE NFKB1
22 response to interferon-beta GO:0035456 9.59 IKBKE STAT1
23 response to type I interferon GO:0034340 9.58 IKBKE MX1
24 response to cytokine GO:0034097 9.58 PML STAT1
25 positive regulation of interferon-alpha production GO:0032727 9.58 DDX58 IRF3 STAT1
26 detection of virus GO:0009597 9.57 DDX58 TLR3
27 type I interferon signaling pathway GO:0060337 9.55 IFNA4 IRF3 MX1 STAT1 STAT2
28 response to virus GO:0009615 9.43 CCL5 CXCL10 DDX58 IFNA4 MX1 TLR3
29 defense response to virus GO:0051607 9.28 CXCL10 DDX58 IFNA4 IRF3 MX1 PML
30 cellular response to dsRNA GO:0071359 9.07 NFKB1
31 signal transduction GO:0007165 10.19 CXCL10 MX1 NFKB1 NGFR STAT1 STAT2
32 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 CXCL10 DDX58 IRF3 NFKB1 STAT1 TLR3
33 apoptotic process GO:0006915 10.04 IRF3 MX1 NFKB1 NGFR PML
34 immune system process GO:0002376 10 DDX58 IGHM IRF3 MX1 PML TLR3

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 ALB CCL5 CXCL10 DDX58 IFNA4 IGHM
2 ubiquitin protein ligase binding GO:0031625 9.56 DDX58 IKBKE NGFR PML
3 ubiquitin-like protein ligase binding GO:0044389 9.32 STAT1 STAT2
4 identical protein binding GO:0042802 9.28 ALB CCL5 DDX58 IRF3 MX1 NFKB1
5 CCR5 chemokine receptor binding GO:0031730 9.16 CCL5 STAT1

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....